Company intelligence / Profile preview

Cibiem

California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 1

Overview

Cibiem developed a proprietary, minimally invasive catheter-based approach for ablation of the carotid body to modulate sympathetic nervous system activity. The company’s CBM technology was tested in first-in-human trials targeting treatment-resistant hypertension and other diseases linked to sympathetic overactivity. Clinical results focused on safety and feasibility, with the goal to reduce blood pressure by ablating the carotid body. No published pivotal or late-stage results are available.

Therapeutic areas: CardiovascularEndocrinologyNephrology
Modalities: DeviceCatheter-based therapyAblation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Catheter-based carotid body ablation system

Phase 1

Indications: Heart failure, Hypertension, Diabetes, Renal failure

Beyond the preview

Go deeper on Cibiem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cibiem.

Explore the full profile